The Marked Chart Wire · Health
Cognition
Cognition plans mid-2027 trial start for DLB
Cognition outlined a plan to begin Phase III trials for DLB in mid-2027. The company stated it has sufficient cash to operate through the fourth quarter of 2027.
Learn the basics
New to this? Read: Reading a stock chart
More Health news
Arcturus
Arcturus to start Phase II trial of ARCT-2601 next quarter
Arcturus intends to initiate Phase II testing of its ARCT-2601 drug candidate next quarter. The company anticipates releasing preliminary results in the second half of 2027, following a 38-fold improvement in potency for the LUNAR 2.0 program.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.